LOXHD1

Across TCGA pan-cancer cohorts, LOXHD1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated LOXHD1 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher LOXHD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LOXHD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

KIRC, BRCA, and UCEC are the cancer types where LOXHD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.176	0.813	<.001	36	view →
BRCA	OS	Median	All	0.721	0.926	<.001	28	view →
UCEC	OS	Median	III,IV	0.933	0.539	.018	24	view →
SARC	DFS	Median	All	0.222	0.620	<.001	13	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SCLC	DFS	Median	II,III,IV	1.000	0.303	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

LOXHD1–KIRC (OS)

Open the KIRC breakdown →